Tools chosen: kalshi_direct claude_news gdelt_news polymarket_related kalshi_related wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This resolves Yes if any calendar year 2024-2029 has zero reported wild poliovirus type 1 cases globally. WPV1 is now endemic only in Pakistan and Afghanistan, so the key research is recent annual case counts, the trend trajectory, environmental surveillance signals, and GPEI eradication timeline credibility. The Kalshi price is the primary anchor; news and background sources fill in the epidemiological facts.

# Current state No calendar year has had zero wild poliovirus type-1 (WPV1) cases in the eligible window; 2023 hit a record low of 12 cases but 2024 rebounded sharply to ~96-99 cases, and 2025 is tracking at 38 cases through Oct 22 (down from 62 in the same period of 2024, per GDELT/news dated into 2026 suggesting a further decline trend but still far from zero). Resolution requires a full year (2024-2029) with 0 reported WPV1 cases; 2024 already resolved with ~96-99 cases, so it did NOT trigger Yes. # Timeline of key events - 2021: WPV1 cases hit a historic low of 6 globally (confirmed, Wikipedia/CDC). - 2023: 12 WPV1 cases globally (6 Afghanistan, 6 Pakistan) — record low (confirmed, multiple sources). - 2024 (through year-end): Cases surge to 96-99 globally (Pakistan ~71-74, Afghanistan ~25); environmental positive samples triple to 581 (confirmed, WHO/CDC/claude_news). Pakistan reverts to national house-to-house campaign restrictions (Sept 2024, confirmed, CDC MMWR). Attacks on vaccination teams reported (confirmed, CIDRAP). - 2025-02: Saudi Arabia pledges $500M to GPEI (confirmed, Think Global Health). - 2025 (early): US withdraws USAID/CDC support from GPEI, creating ~$233M/yr shortfall; ~30,000 trained polio workers' program affected (confirmed, Health Policy Watch/Rolling Stone). - 2025-04: WHO/GPEI reaffirms interruption target of 2027 for WPV1, 2029 for cVDPV2, with $2.3B funding-need increase under extended 2022-2029 strategy (confirmed, WHO/EMRO). - 2025 (through Oct 22): 38 WPV1 cases reported globally, down from 62 in same period 2024 (confirmed, claude_news); environmental surveillance detects 80 positive samples (9 Afghanistan, 71 Pakistan), including outside core areas (confirmed). - 2026 (Jul-Aug, per GDELT — dates likely mis-tagged/future-dated, treat cautiously): Continued new case reports in Afghanistan (Uruzgan, 6 new cases amid returnee influx), Pakistan environmental positivity declining to 13.1%, ongoing vaccination campaigns, WHO warning of 150 closed health centers in Afghanistan threatening eradication (reported, GDELT — note dates appear anomalous/possibly system-clock artifacts). # Event Will a full calendar year between 2024 and 2029 record zero reported wild poliovirus type-1 (WPV1) cases globally (Kalshi: KXPOLIOELIM-30)? # Outcomes to forecast Yes / No # Kalshi market anchor **Current YES price: 7.60%** (implies ~92.4% chance of No). 7-day change: +1.2pp; 30-day change: +2.0pp — slight upward drift. Price range over 37 days: 4.00%–12.70%. Average daily volume: 85 contracts (thin/low-liquidity market). No related Kalshi or Polymarket markets found (0 matches on both). # Sub-question answers 1. **WPV1 cases 2023/2024/2025 by country** — 2023: 12 total (6 Afghanistan, 6 Pakistan). 2024: ~96-99 total (Pakistan 71-74, Afghanistan 25). 2025 (through Oct 22): 38 total, all in Afghanistan/Pakistan, down from 62 in same period 2024 [claude_news, CDC, Wikipedia]. 2. **Environmental surveillance trend** — Positive samples nearly quadrupled from 127 (2023) to 581 (2024); 2025 shows 80 positives (9 Afghanistan, 71 Pakistan) with detections beyond core transmission zones and during low-transmission season, suggesting continued silent spread, though Pakistan's positivity rate reportedly declined to 13.1% by mid-2026 [claude_news, GDELT/dunyanews]. 3. **GPEI target date** — Official target: interrupt WPV1 transmission by 2027, certify cVDPV2 elimination by 2029, under the extended 2022-2029 strategy (funding need raised to $6.9B) [WHO/EMRO, April 2025]. This is itself an extension from earlier targets (originally 2000, then repeatedly pushed — 2018, 2023, now 2027), reflecting a decade-plus pattern of slippage. 4. **Vaccination access** — Mixed/negative: Pakistan reverted to national restrictions on house-to-house campaigns (Sept 2024); attacks on vaccination teams continued in Pakistan (Balochistan bombing killed 9); Afghanistan faces repatriation-driven population churn, female-participation restrictions, and 150 health center closures threatening program reach [CDC MMWR, CIDRAP, GDELT/Khaama]. 5. **Did 2024 hit zero?** — No. 2024 recorded ~96-99 WPV1 cases, the opposite of zero — a major resurgence year, so Yes did not trigger. 6. **Base-rate probability of a zero year 2025-2029** — Monte Carlo simulation (Negative Binomial, calibrated to 2015-2024 mean=62.9, high overdispersion) gives P(single year=0) ≈0.8-1%, and P(≥1 zero year in 5 years) ≈4.4% under current trend continuation; sensitivity analysis shows this could range 2-24% depending on whether true mean falls toward single digits (λ=5→23.7%) or stays elevated (λ=50→0.09%) [code_execution]. 7. **Funding cuts impact** — Yes, materially: US withdrawal of USAID/CDC support created ~$233M/year shortfall and disrupted a 30,000-worker surveillance network responsible for identifying >40% of 2025 case detections; partially offset by Saudi Arabia's $500M pledge (Feb 2025) [Health Policy Watch, Rolling Stone, Think Global Health]. # Key facts (high-confidence, factual) 1. [Wikipedia/CDC] Only Afghanistan and Pakistan remain WPV1-endemic; all wild cases since 2020 are WPV1 (WPV2/WPV3 already eradicated). 2. [claude_news/WHO] 2024 cases (~96-99) represented a >5x increase in Pakistan and >2.8x in Afghanistan vs. 2023's record-low 12. 3. [claude_news] 2025 cases (38 through Oct 22) are down ~39% YoY but far from zero. 4. [code_execution] Historical 2015-2024 annual mean ≈63 cases, std≈58 — highly volatile, no statistically significant mean-reversion toward zero. # Cross-market signals - Kalshi related: only the same KXPOLIOELIM-30 ticker found; no distinct sub-markets. - Polymarket: no matching markets (0/100 scanned). - Sportsbook implied: not applicable (health/epidemiology market). # Analyst opinions and speculation - claude_news synthesis: reaching zero before 2030 is "uncertain but not impossible" only if the 2027 target is met and followed by a clean year. - IMB (Independent Monitoring Board) called USAID/CDC funding cuts "a devastating blow to the infrastructure." - Nature (GDELT) ran a piece questioning "Can the world finally eradicate polio?" — reflects ongoing expert skepticism/hope mix, not a firm forecast. # Directional lean per outcome - **Yes**: Supported by declining 2025 case counts vs 2024, Saudi funding boost, historical precedent of a near-miss low (2021: 6 cases; 2023: 12 cases). Opposed by no zero-year ever achieved, GPEI's own history of missed deadlines, funding cuts, ongoing access/security barriers, and quant model estimating only ~4-5% likelihood. - **No**: Strongly favored — persistent transmission, environmental surveillance detecting virus beyond core areas, security/access disruptions, funding shortfalls, and statistical modeling all point to continued non-zero years through 2029. # Gaps / unknowns - No official 2026-2029 case data exists yet (all forward years unresolved); GDELT results dated 2026 appear anomalous/possibly mis-timestamped and should be treated cautiously. - Uncertain whether 2027 GPEI target will be met given recent slippage history. - Unclear how funding cuts will evolve (further cuts vs. new donors) affecting future case trajectories. # Calibration anchors - Kalshi current YES price: 7.60% (primary anchor). - Quant model estimate: ~4-5% P(Yes), consistent with Kalshi pricing. - Historical precedent: no country pair (Afghanistan/Pakistan) has ever posted a joint zero-case year during endemic period; closest was 2021 (6 cases) which then rebounded.

1. Both forecasts converge almost exactly on ~6-6.5% Yes, essentially just parroting the Kalshi price and quant model without independently stress-testing the model's key assumption (Negative Binomial with mean~63); the brief's own sensitivity analysis shows P(Yes) could range 2-24% depending on whether the true underlying rate is shifting toward single digits (λ=5→23.7%), and neither forecaster grapples with the fact that 2025's 38 cases (down 39% YoY) could indicate exactly this kind of regime shift rather than continuation of the 2015-2024 mean. 2. Neither forecast addresses the resolution-timing asymmetry: even if transmission is interrupted per the 2027 GPEI target, achieving a genuine full-calendar-year zero requires zero cases AND zero silent transmission surfacing later — but the brief notes environmental surveillance already reveals "detections beyond core transmission zones during low-transmission season," suggesting even a nominal "zero case" year could still have undetected chains, a nuance both forecasts gloss over. 3. Both forecasters treat funding cuts and Saudi Arabia's $500M pledge as roughly netting out to "material headwinds," but neither quantifies whether the pledge actually restores the $233M/year shortfall or falls short over the 2025-2029 window — this funding trajectory is a key unresolved uncertainty per the brief that could swing the probability more than the ~1-2pp adjustment applied. 4. Neither forecast discusses tail scenarios in either direction: e.g., a security collapse in Afghanistan (150 health center closures, repatriation churn) that pushes cases up further making Yes even less likely, versus a surprise ceasefire/access breakthrough in Pakistan or Afghanistan that could cause a sharp drop — both forecasts implicitly assume smooth continuation rather than considering these low-probability but nontrivial discontinuities. 5. Both forecasts anchor confidence around 0.72-0.74 despite the market being thinly traded (85 contracts/day, price range 4-12.7% over 37 days) — this volatility and illiquidity suggests the "anchor" itself carries more uncertainty than treated, yet both forecasters lean on it as a stable calibration point. 6. Neither forecast explicitly addresses why they landed below the Kalshi price (7.6%) rather than at or above it, given that the +1.2pp/+2.0pp upward drift in the market could reflect real-time information (e.g., improving 2025 case trends) that hasn't been fully incorporated into their reasoning — this slight downward deviation from market consensus is asserted but not well justified beyond citing the quant model, which itself has wide uncertainty bounds.

7% (73% confidence)

Yes: 7% No: 93%

Both forecasts landed at 6-6.5%, just below the 7.6% Kalshi anchor, citing the quant model's ~4-5% estimate. The red-team critique's strongest point is that the market's recent upward drift may already reflect the improving 2025 trend (38 cases through Oct, -39% YoY), and the model's sensitivity analysis shows P(Yes) rises substantially if the underlying rate is shifting to single digits — arguing against pushing below the anchor. However, structural barriers remain severe: no zero year has ever occurred, environmental surveillance shows silent spread beyond core zones, funding is disrupted, and the 2021/2023 lows both rebounded sharply. I split the difference by settling at the market anchor rather than below it, giving Yes 7%.

Total pipeline time: 199.8s